crizanlizumab

Crizanlizumab is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin, a cell adhesion molecule expressed on activated platelets and vascular endothelial cells. By blocking the interaction between P-selectin and its ligands, including P-selectin glycoprotein ligand 1 (PSGL-1) on leukocytes and red blood cells, crizanlizumab inhibits the cellular interactions that contribute to vaso-occlusion in sickle cell disease. This mechanism reduces the frequency of painful vaso-occlusive crises in patients with sickle cell disease aged 16 years and older. Crizanlizumab can be used as monotherapy or as an add-on to hydroxyurea/hydroxycarbamide for patients who are inappropriate candidates for or inadequately managed by hydroxyurea. The drug was developed by Novartis[3][5][6][8].

Brand names

Adakveo

Other names

crizanlizumab-tmca